Febrile Rash Illness Research Articles

Measles - United States, January 1, 2020-March 28, 2024.

Measles is a highly infectious febrile rash illness and was declared eliminated in the United States in 2000. However, measles importations continue to occur, and U.S. measles elimination status was threatened in 2019 as the result of two prolonged outbreaks among undervaccinated communities in New York and New York City. To assess U.S. measles elimination status after the 2019 outbreaks and to provide context to understand more recent increases in measles cases, CDC analyzed epidemiologic and laboratory surveillance data and the performance of the U.S. measles surveillance system after these outbreaks. During January 1, 2020-March 28, 2024, CDC was notified of 338 confirmed measles cases; 97 (29%) of these cases occurred during the first quarter of 2024, representing a more than seventeenfold increase over the mean number of cases reported during the first quarter of 2020-2023. Among the 338 reported cases, the median patient age was 3 years (range=0-64 years); 309 (91%) patients were unvaccinated or had unknown vaccination status, and 336 case investigations included information on ≥80% of critical surveillance indicators. During 2020-2023, the longest transmission chain lasted 63 days. As of the end of 2023, because of the absence of sustained measles virus transmission for 12 consecutive months in the presence of a well-performing surveillance system, U.S. measles elimination status was maintained. Risk for widespread U.S. measles transmission remains low because of high population immunity. However, because of the increase in cases during the first quarter of 2024, additional activities are needed to increase U.S. routine measles, mumps, and rubella vaccination coverage, especially among close-knit and undervaccinated communities. These activities include encouraging vaccination before international travel and rapidly investigating suspected measles cases.

Viral Pathogenic Spectrum and Epidemiological Characteristics of Febrile Rash Illness in China From 2009 to 2021

Objective: The aim of this study was to monitor the spectrum of viral pathogens involved in febrile rash illness (FRI) and their epidemiology. Methods: A large-scale study was conducted in multiple provinces of China from 2009 to 2021. A total of 14,168 patients of all age groups were enrolled and tested for seven common viruses causing FRI: measles virus (MV), rubella virus (RuV), enterovirus (EV), varicella zoster virus (VZV), human parvovirus B19 (HPV B19), human herpes virus 6 (HHV6), and dengue virus (DENV). Results: Of 14,168 patients with FRI, 9,443 tested positive for a virus, thus yielding a viral positivity rate of 66.65%. Among the seven viruses detected, EV (61.04%), MV (23.32%), RuV (7.74%), and VZV (5.26%) had high detection rates and exhibited different age-specific positivity rates and seasonal prevalence patterns. Early in the Coronavirus Disease 2019 (COVID-19) pandemic, the number of EV, MV, RuV, and VZV cases significantly declined, and the seasonal patterns also changed in 2020, with delay or disappearance of traditional epidemic peaks. Conclusions: EV, MV, RuV, and VZV were found to be the main causal pathogens of FRI among patients in China, and their epidemic levels and seasonal patterns changed during the COVID-19 pandemic, because of large-scale implementation of non-pharmacological interventions.

The epidemiological and genetic characteristics of human parvovirus B19 in patients with febrile rash illnesses in China

To understand the epidemiological and genetic characteristics of B19V, a multiple-province surveillance of patients with febrile rash illnesses (FRIs) were conducted in China during 2009 ~ 2021. The clinical specimens of 3,820 FRI patients were collected and tested for B19V DNA. A total of 99 (2.59%) patients were positive for B19V, and 49 (49.49%) were children under 5 years old. B19V infections occurred throughout the year without obvious seasonal pattern. Ten NS1-VP1u sequences and seven genome sequences were obtained in this study, identified as subgenotype 1a. Combined with the globally representative genome sequences, no temporal and geographic clustering trends of B19V were observed, and there was no significant correlation between B19V sequences and clinical manifestations. The evolutionary rate of the B19V genome was 2.30 × 10–4 substitutions/site/year. The number of negative selection sites was higher than that of positive selection sites. It was the first to comprehensively describe the prevalence patterns and evolutionary characteristics of B19V in FRI patients in China. B19V played the role in FRI patients. Children under 5 years old were the main population of B19V infection. Subgenotype 1a was prevalent in FRI patients in China. B19V showed a high mutation rate, while negative selection acted on the genome.

Profile of cardiac lesions among laboratory confirmed congenital rubella syndrome (CRS) infants: a nationwide sentinel surveillance, India, 2016-22.

The phenotypical profile of cardiovascular malformations in patients with congenital rubella syndrome (CRS) is varied. We aimed to describe the profile of cardiac defects among CRS patients detected in the sentinel CRS surveillance in India during 2016-22. Sentinel sites enrolled infants with suspected CRS based on presence of cardiac defects, hearing impairment, eye signs, or maternal history of febrile rash illness. Suspected CRS cases underwent detailed systemic examination, including echocardiography and serological investigation for rubella. Cardiac defects were categorized as 'Simple' or 'Complex' as per the National Heart, Lung, and Blood Institute classification. We compared the distribution of cardiac defects among laboratory confirmed CRS cases and seronegative discarded cases. Of the 4578 suspected CRS cases enrolled by 14 sites, 558 (12.2%) were laboratory confirmed. 419 (75.1%) laboratory confirmed cases had structural heart defects (simple defects: n=273, 65.2%, complex defects: n=144, 34.4%), with ventricular septal defect (42.7%), atrial septal defect (39.4%), patent ductus arteriosus (36.5%), and tetralogy of Fallot as the commonest defects (4.5%). Laboratory confirmed CRS cases had higher odds of left to right shunt lesions (OR=1.58, 95% CI: 1.15-2.17). This was mainly on account of a significant association of PDA with CRS (OR=1.77, 95% CI: 1.42-2.21). Mortality was higher among CRS patients with complex heart defects (HR=2.04, 95% CI: 1.26-3.30). Three-fourths of the laboratory confirmed CRS cases had structural heart defects. CRS patients with complex cardiac defects had higher mortality. Detecting CRS infection early and providing timely intervention for cardiovascular defects is critical for the management of CRS patients. Ministry of Health and Family Welfare, Govt of India, through Gavi, the Vaccine Alliance.

Measles virus transmission patterns and public health responses during Operation Allies Welcome: a descriptive epidemiological study

On Aug 29, 2021, Operation Allies Welcome (OAW) was established to support the resettlement of more than 80 000 Afghan evacuees in the USA. After identification of measles among evacuees, incoming evacuee flights were temporarily paused, and mass measles vaccination of evacuees aged 6 months or older was introduced domestically and overseas, with a 21-day quarantine period after vaccination. We aimed to evaluate patterns of measles virus transmission during this outbreak and the impact of control measures. We conducted a measles outbreak investigation among Afghan evacuees who were resettled in the USA as part of OAW. Patients with measles were defined as individuals with an acute febrile rash illness between Aug 29, 2021, and Nov 26, 2021, and either laboratory confirmation of infection or epidemiological link to a patient with measles with laboratory confirmation. We analysed the demographics and clinical characteristics of patients with measles and used epidemiological information and whole-genome sequencing to track transmission pathways. A transmission model was used to evaluate the effects of vaccination and other interventions. 47 people with measles (attack rate: 0·65 per 1000 evacuees) were reported in six US locations housing evacuees in four states. The median age of patients was 1 year (range 0-26); 33 (70%) were younger than 5 years. The age distribution shifted during the outbreak towards infants younger than 12 months. 20 (43%) patients with wild-type measles virus had rash onset after vaccination. No fatalities or community spread were identified, nor further importations after flight resumption. In a non-intervention scenario, transmission models estimated that a median of 5506 cases (IQR 10-5626) could have occurred. Infection clusters based on epidemiological criteria could be delineated into smaller clusters using phylogenetic analyses; however, sequences with few substitution count differences did not always indicate single lines of transmission. Implementation of control measures limited measles transmission during OAW. Our findings highlight the importance of integration between epidemiological and genetic information in discerning between individual lines of transmission in an elimination setting. US Centers for Disease Control and Prevention.

MPOX: A RE-EMERGING INFECTION

World Health Organization (WHO)'s declaration on July 23, 2022 regarding Mpox (previously Monkey pox) outbreak appeared as Public Health Emergency of International Concern (PHEIC). Although, WHO, in May 2023 declared an end to the global health emergency for Mpox, but still, it is still prevalent and public awareness should continue.1 This viral Zoonotic contagious disease was first discovered in 1958 when two outbreaks occurred in monkeys kept for research in Denmark, hence the name “monkeypox”. The first human case of monkeypox was recorded in 1970 in the Democratic Republic of Congo.2
 Orthopoxvirus infections can cause a spectrum of febrile rash illnesses in humans, ranging from fairly benign, localized skin infections to severe systemic infections. Other diseases confused with vesicular rashes are smallpox, generalized vaccinia (vaccinia is the virus used in smallpox vaccination), disseminated herpes zoster, disseminated herpes simplex, drug eruptions, erythema multiforme, buffalopox, scabies, enteroviral infections, insect bites, impetigo, molluscum contagiosum, meningococcemia, and idiopathic thrombocytopenic purpura. The most striking feature that distinguishes Mpox from others is the presence of cervical lymphadenopathy, while in all other orthopoxviral infections this feature is absent.3,5
 When suspicion is strong, nucleic acid amplification testing (NAAT), using real-time or conventional PCR Polymerase chain reaction (PCR) is the preferred laboratory test. The recommended specimen type for laboratory confirmation of Mpox is skin lesion material, including swabs of lesion surface and/or exudate, roofs
 from more than one lesion, or lesion crusts. Many individuals infected with Mpox virus have a mild, self-limiting disease course in the absence of specific therapy. However, in the case of severe disease, treatment after infectious diseases consultation should be considered with vaccinia immunoglobulin intravenous (VIGIV), and antivirals brincidofovir or tecovirimat.2 The prognosis for Mpox depends on multiple factors such as previous vaccination status, initial health status, and concurrent illnesses or comorbidities.6 In addition to infection control measures, people need to get vaccinated, where available, for the best protection against mpox.2
 National Institute of Health (NIH), Islamabad, Pakistan, under guidance of Ministry of National Health Services Regulations & Coordination (NHSR&C) has issued the National Guidelines for Mpox. NIH has also developed the bottom-up approach for the flow of information and reporting.7 The relationship between Mpox and smallpox has raised anxieties and misperceptions among the public, patients, and healthcare providers. Misinformation about Mpox has already begun to circulate. The public need to be engaged. Targeted risk-communication strategies should be developed. There is also need for regions to maintain public health preparedness and response. This warrants the strongest medical, scientific, and political global effort.

The protective roles of liraglutide on Kawasaki disease via AMPK/mTOR/NF-κB pathway.

Kawasaki disease (KD) is an acute febrile rash illness among children of unknown etiology, with coronary artery injury. The main purpose of this study was to investigate the protective effects of liraglutide on KD, and elucidate the underlying mechanisms. The candida albicans water-soluble fraction (CAWS)-induced coronary arteritis of mouse KD model in vivo and tumor necrosis factor α (TNF-α) induced endothelial cell injury of human umbilical vein endothelial cell (HUVEC) model in vitro were used to explore the anti-inflammation and anti-apoptosis effects of liraglutide on KD. In vivo results showed that liraglutide could significantly alleviate the coronary artery injury of KD mice, as evidenced by the reduction of inflammatory infiltration around the coronary arteries, downregulation of inflammatory cytokines and chemokines expressions, and decrease of TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labeling) positive cell rates. The results in vitro also displayed that liraglutide could markedly relieve the inflammatory of TNF-α induced HUVECs through downregulating the expressions of inflammatory and chemokine indicators as well as inhibit TNF-α induced HUVEC apoptosis by the less ratio of apoptotic cells, the more loss of mitochondrial membrane potential (△Ψm), the lower level of intracellular reactive oxygen species (ROS), and the more ratio of BCL-2/BAX. Further in vivo and in vitro studies demonstrated that liraglutide could rescue endothelial cell injury through AMPK/mTOR/NF-κB pathway. In conclusion, liraglutide could play protective roles on KD through inhibiting endothelial cell inflammation and apoptosis via the activation of AMPK/mTOR/NF-κB pathway.

Molecular Detection of Measles Virus from Febrile Rash Illness Cases in Lagos State, Nigeria

Measles virus, an RNA virus of the genus Morbillivirus in the family Paramyxoviridae, is the etiological agent of measles disease, the fifth worldwide cause of death in children < 5 years of age. Despite the ongoing immunization progress in Nigeria, several sporadic cases and outbreaks of measles are still being reported annually, even among the immunized in the country. Continuous surveillance and early detection by laboratory diagnosis is of importance for early management of cases and prompt containment of community spread. Reverse Transcription Polymerase Chain Reaction (RT-PCR) testing was used for prompt diagnosis of all febrile rash illness (FRI) cases captured during routine disease surveillance activities in selected Health Facilities in Lagos State from 2016 to 2018. Whole blood or throat swab samples were collected and screened by RT-PCR from 140 consenting FRI patients accessing selected health facilities in Lagos State, Nigeria. Nine (6.4%) out of the 140 samples screened by RT-PCR were positive for Measles RNA. All the 9 measles positive cases were from children ages 1 – 5 years with females being more infected than males in ratio 3:1, although without any statistical significance (p= 0.7735). Out of eight Local Government Areas (LGAs) where FRI cases were sampled, only two of them (Eti-Osa and Lagos Mainland LGAs) account for the nine measles positive cases detected in this work. It is however a possibility that the number of LGAs with positive measles cases could have been more than two if all health facilities in the sampled LGAs were selected for the work, but within the limit of available resources, all health facilities could not be sampled.

A case of measles in a Nepalese child: where are we failing?

Measles affected more than 90% of children under 15 years of age and caused 2-3 million measles-associated deaths globally each year before the introduction of vaccines against it. Today, measles vestiges a leading cause of vaccine-preventable illness worldwide, causing more than 100,000 deaths annually. Characterized by a febrile rash illness, measles is often self-resolving. However, significant complications can occur including encephalitis with permanent neurologic sequelae and death in one to three out of 1000 measles cases. Although global measles elimination is a WHO goal, current trends in the epidemiology of measles and vaccine hesitancy suggest that this goal is not yet attainable. As the most highly transmissible vaccine-preventable disease, measles is especially subtle to changes in herd immunity, the impact of vaccine refusal and globalization.

Progress Toward Rubella and Congenital Rubella Syndrome Control and Elimination — Worldwide, 2012–2020

Rubella virus is a leading cause of vaccine-preventable birth defects and can cause epidemics. Although rubella virus infection usually produces a mild febrile rash illness in children and adults, infection during pregnancy, especially during the first trimester, can result in miscarriage, fetal death, stillbirth, or an infant born with a constellation of birth defects known as congenital rubella syndrome (CRS). A single dose of rubella-containing vaccine (RCV) can provide lifelong protection against rubella (1). The Global Vaccine Action Plan 2011-2020 (GVAP) included a target to achieve elimination of rubella in at least five of the six World Health Organization (WHO) regions* by 2020 (2), and WHO recommends capitalizing on the accelerated measles elimination activities as an opportunity to introduce RCV (1). This report updates a previous report (3) and summarizes global progress toward control and elimination of rubella and CRS from 2012, when accelerated rubella control activities were initiated, through 2020. Among 194 WHO Member States, the number with RCV in their immunization schedules has increased from 132 (68%) in 2012 to 173 (89%) in 2020; 70% of the world's infants were vaccinated against rubella in 2020. Reported rubella cases declined by 48%, from 94,277 in 2012 to 49,136 in 2019, and decreased further to 10,194 in 2020. Rubella elimination has been verified in 93 (48%) of 194 countries including the entire Region of the Americas (AMR). To increase the equity of protection and make further progress to eliminate rubella, it is important that the 21 countries that have not yet done so should introduce RCV. Likewise, countries that have introduced RCV can achieve and maintain rubella elimination with high vaccination coverage and surveillance for rubella and CRS. Four of six WHO regions have established rubella elimination goals; the two WHO regions that have not yet established an elimination goal (the African [AFR] and Eastern Mediterranean [EMR] regions) have expressed a commitment to rubella elimination and should consider establishing a goal.

#25: Contemporaneous Evaluation of Kawasaki Disease and Multisystem Inflammatory Syndrome in Children Cases in Northern Virginia

BackgroundMultisystem inflammatory syndrome in children (MIS-C) has a temporal association with SARS-coronavirus 2 (SARS-CoV-2) infection and can present similarly to Kawasaki disease (KD). After the Centers for Disease Control and Prevention issued a MIS-C case definition in May 2020, we implemented local diagnostic and management strategies to standardize the care for patients with MIS-C encouraging limited laboratory evaluation of non-toxic patients presenting with a febrile illness. We then sought to re-evaluate our diagnostic and management recommendations to ensure appropriate resource utilization for children with MIS-C and KD.MethodsPatients with MIS-C and KD were identified via convenience sampling of Pediatric Infectious Diseases clinical records at Inova Children’s Hospital from May 1, 2020 to August 28, 2020. Manual chart review was done to extract clinical points of interest and the two cohorts were compared with descriptive statistics. Abdominal symptoms included pain, emesis, and diarrhea. Respiratory symptoms included shortness of breath, tachypnea, cough, and need for mechanical ventilation. Musculoskeletal symptoms included pain and edema. Neurologic symptoms included headache, dizziness, altered mental status, and irritability.Results7 patients with KD and 14 patients with MIS-C were identified. No patients with KD had presenting hypotension and 9 patients with MIS-C had presenting hypotension (p < 0.01). Oral changes were seen in 5 patients with KD and 3 patients with MIS-C (p = 0.05). Conjunctival injection, rash, abdominal symptoms, musculoskeletal symptoms, and neurologic symptoms were seen in some patients with KD and MIS-C with no statistically significant occurrence of these symptoms between the two cohorts. The median initial absolute lymphocyte count was 2,860/µL in KD cases whereas it was 1,325/µL in MIS-C cases (p < 0.01). The median platelet count was 367,000/ µL in KD cases versus 193,000 in MIS-C cases (p = 0.03). The median initial C-reactive protein was 11.2 mg/dL in KD cases versus 23.2 mg/dL in MIS-C cases (p < 0.01). There was no statistically significant difference in the white blood cell count, erythrocyte sedimentation rate, alanine transaminase, B-natriuretic peptide, troponin I, or ferritin values between KD and MIS-C patients. Coronary artery dilation or prominence was seen in 4 patients with KD and in 8 patients with MIS-C (p > 0.99). There were no deaths.ConclusionsFollowing national recognition of MIS-C we saw approximately 1 MIS-C case per week. Presenting hypotension, an absolute lymphocyte count less than 1400/µL, a platelet count less than 200,000/µL, and a CRP greater than 20 mg/dL best predicted MIS-C versus KD. The initial white blood cell count, alanine transaminase, erythrocyte sedimentation rate, B-natriuretic peptide, troponin I, ferritin, and initial coronary artery dilation did not readily distinguish KD from MIS-C. Thus, our diagnostic management recommending limited laboratory evaluation for non-toxic patients presenting with a febrile rash illness, fever and abdominal symptoms, or fever with conjunctival injection is reasonable.

Progress Toward Rubella Elimination - World Health Organization European Region, 2005-2019.

In 2005, the Regional Committee of the World Health Organization (WHO) European Region (EUR) passed a resolution calling for the regional elimination of measles, rubella, and congenital rubella syndrome (CRS) (1). In 2010, all 53 countries in EUR* reaffirmed their commitment to eliminating measles, rubella, and CRS (2); this goal was included in the European Vaccine Action Plan 2015-2020 (3,4). Rubella, which typically manifests as a mild febrile rash illness, is the leading vaccine-preventable cause of birth defects. Rubella infection during pregnancy can result in miscarriage, fetal death, or a constellation of malformations known as CRS, which usually includes one or more visual, auditory, or cardiac defects (5). The WHO-recommended measles and rubella elimination strategies in EUR include 1) achieving and maintaining ≥95% coverage with 2 doses of measles- and rubella-containing vaccine (MRCV) through routine immunization services; 2) providing measles and rubella vaccination opportunities, including supplementary immunization activities (SIAs), to populations susceptible to measles or rubella; 3) strengthening surveillance by conducting case investigations and confirming suspected cases and outbreaks with laboratory results; and 4) improving the availability and use of evidence to clearly communicate the benefits and risks of preventing these diseases through vaccination to health professionals and the public (6). This report updates a previous report and describes progress toward rubella and CRS elimination in EUR during 2005-2019 (7). In 2000, estimated coverage with the first dose of a rubella-containing vaccine (RCV1) in EUR was 60%, and 621,039 rubella cases were reported (incidence = 716.9 per 1 million population). During 2005-2019, estimated regional coverage with RCV1 was 93%-95%, and in 2019, 31 (58%) countries achieved ≥95% coverage with the RCV1. During 2005-2019, approximately 38 million persons received an RCV during SIAs in 20 (37%) countries. Rubella incidence declined by >99%, from 234.9 cases per 1 million population (206,359 cases) in 2005 to 0.67 cases per 1 million population (620 cases) by 2019. CRS cases declined by 50%, from 16 cases in 2005 to eight cases in 2019. For rubella and CRS elimination in EUR to be achieved and maintained, measures are needed to strengthen immunization programs by ensuring high coverage with an RCV in every district of each country, offering supplementary rubella vaccination to susceptible adults, maintaining high-quality surveillance for rapid case detection and confirmation, and ensuring effective outbreak preparedness and response.

The Epidemiology of Rubella in Lesotho before the Introduction of a Rubella Containing Vaccine: A Review of Measles Case-based Surveillance, 2012-2016

Aim: The aim of the study was to determine the burden and epidemiology of rubella infection in Lesotho before the introduction of a rubella-containing vaccine. It was also to assess the performance of the measles case-based surveillance system in Lesotho.&#x0D; Study Design: Retrospective cross-sectional descriptive study.&#x0D; Place and Duration of Study: The study was done in Lesotho from February to March 2019 based on the 2012 to 2016 data.&#x0D; Methods: There was a review of the measles case-based surveillance data with a total of 1587 suspected cases reported during the study period. Samples were collected from suspected measles cases and tested for measles. Those samples that tested negative for measles were subsequently tested for rubella IgM at the National Reference Laboratory. The serum samples were analysed for rubella IgM using commercial enzyme-linked immunosorbent assay (ELISA) kits SERION and EUROIMMUN.&#x0D; Results: There were 2 measles IgM and 748 rubella IgM positive cases confirmed. The rubella IgM positive cases accounted for 48% of the samples tested for rubella infection. There were also several rubella outbreaks during the study period. The Lesotho surveillance system met the two principal surveillance performance indicators for each year during the period of the study.&#x0D; Conclusion: This study showed that there was high level of rubella sero-positivity with several outbreaks of rubella infections during the study period. Rubella infection was predominantly seen in those aged between 5 and &lt;13 years of age. This justified the introduction of a rubella containing vaccine in Lesotho in 2017. Although the two principal surveillance performance indicators (non-measles febrile rash illness rates and the percentage of districts that reported at least one case of measles with blood specimen per year) were met during the period under review, there were districts that performed poorly. This study revealed the need for strengthening of rubella-containing vaccine component of routine immunization to lower the impact of rubella infection in Lesotho. A detailed district level review to identify and address the causes of poor performance in some districts is recommended. There is also a need to identify the current challenges and evaluate the impact of the recently introduced rubella-containing vaccine on rubella infection in Lesotho.

The impact of the COVID-19 pandemic on measles surveillance in the World Health Organisation African Region, 2020.

Introductionfollowing the declaration of the COVID-19 pandemic, many countries imposed restrictions on public gatherings, health workers were repurposed for COVID-19 response, and public demand for preventive health services declined due to fear of getting COVID-19 in health care settings. These factors led to the disruption in health service delivery, including childhood immunization, in the first months of the pandemic. Measles surveillance supported with laboratory confirmation, is implemented in the African Region as part of the strategies towards attaining measles elimination. World Health Organisation developed guidelines to assist countries to continue to safely provide essential health services including immunization and the surveillance of vaccine preventable diseases during the pandemic.Methodswe analysed the measles case-based surveillance and laboratory databases for the years 2014 to 2020, to determine the impact of the COVID-19 pandemic on measles surveillance, comparing the performance in 2020 against the preceding years.Resultsthe weekly reporting of suspected measles cases declined starting in April 2020. Twelve countries had more than 50% decline in both the number of reported cases as well as in the number of specimens collected in 2020, as compared to the mean for the years 2014-2018. In 2020, only 30% of the specimens from suspected measles cases arrived at the national laboratory within 3 days of collection. At Regional level, 86% of the districts reported suspected measles cases in 2020, while the non-measles febrile rash illness rate was 2.1 per 100,000 population, which was the lowest rate documented since 2014. Only 11 countries met the targets for the two principal surveillance performance indicators in 2020 as compared to an average of 21 countries in the years 2014-2019.Conclusionthe overall quality of measles surveillance has declined during the COVID pandemic in many countries. Countries should implement immediate and proactive measures to revitalise active surveillance for measles and monitor the quality of surveillance. We recommend that countries consider implementing specimen collection and testing methods that can facilitate timely confirmation of suspected measles cases in remote communities and areas with transportation challenges.

Serological Evidence of Chikungunya Virus Infection Among Suspected Measles Cases in Selected Regions of Kenya: 2008-2014.

Chikungunya virus (family Togavirdae and genus Alphavirus) is an emerging and reemerging virus of public health importance both regionally and globally. In Kenya, about 50-60% of the suspected measles cases remain undiagnosed once measles and rubella is ruled out by immunoglobulin M (IgM) ELISA thus prompted the need to do differential diagnosis on the measles/rubella negative samples. Nothing is known about the role played by chikungunya infection among these suspected measles cases. Febrile rash illness is a common clinical presentation of arboviruses, including chikungunya. In this study, we conducted a serosurvey to explore the possible role of chikungunya infections among suspected measles cases in Kenya that had tested negative for measles and rubella. Sera were tested by commercially available ELISA for the presence of IgG and IgM antibodies against the chikungunya virus. All positive samples for chikungunya by ELISA were confirmed by plaque reduction neutralization test (PRNT), and to rule out cross-reactivity with other alphaviruses a panel of viruses was used, namely o' nyong' nyong, Semliki Forest, and Sindbis viruses. Of the 392 serum samples screened, 0.3% (n = 1) tested positive for IgM antibodies, while 4.6% (n = 18) tested positive for IgG antibodies against the chikungunya virus. PRNT results indicated 2 (11%) chikungunya positives and 7 (38.9%) o' nyong' nyong positives. We recommend awareness among health care providers and improved surveillance for these arboviruses by both serology and molecular testing. Testing for other pathogens should also be done to improve disease detection and diagnosis.

Progress Toward Rubella Elimination - Western Pacific Region, 2000-2019.

Rubella is the leading vaccine-preventable cause of birth defects. Rubella typically manifests as a mild febrile rash illness; however, infection during pregnancy, particularly during the first trimester, can result in miscarriage, fetal death, or a constellation of malformations known as congenital rubella syndrome (CRS), commonly including one or more visual, auditory, or cardiac defects (1). In 2012, the Regional Committee of the World Health Organization (WHO) Western Pacific Region (WPR)* committed to accelerate rubella control, and in 2017, resolved that all countries or areas (countries) in WPR should aim for rubella elimination† as soon as possible (2,3). WPR countries are capitalizing on measles elimination activities, using a combined measles and rubella vaccine, case-based surveillance for febrile rash illness, and integrated diagnostic testing for measles and rubella. This report summarizes progress toward rubella elimination and CRS prevention in WPR during 2000-2019. Coverage with a first dose of rubella-containing vaccine (RCV1) increased from 11% in 2000 to 96% in 2019. During 1970-2019, approximately 84 million persons were vaccinated through 62 supplementary immunization activities (SIAs) conducted in 27 countries. Reported rubella incidence increased from 35.5 to 71.3 cases per million population among reporting countries during 2000-2008, decreased to 2.1 in 2017, and then increased to 18.4 in 2019 as a result of outbreaks in China and Japan. Strong sustainable immunization programs, closing of existing immunity gaps, and maintenance of high-quality surveillance to respond rapidly to and contain outbreaks are needed in every WPR country to achieve rubella elimination in the region.

Development of a multiplex one-step real-time RT-PCR assay for the simultaneous detection of eight viruses associated with febrile rash illnesses

Fever and rash illnesses (FRIs) are a series of common diseases with fever and rashes as clinical manifestations, most of which are caused by viral infection. The rashes of FRIs are generally nonspecific; therefore it is difficult to identify FRI-associated viruses solely based on clinical symptoms. To achieve rapid and accurate identification of FRI pathogens, a multiplex one-step real-time reverse transcription-polymerase chain reaction (RT-PCR) assay was developed and evaluated in this study. Primers and probes were selected for the detection of measles virus (MeV), rubella virus (RV), human enterovirus (EV), varicella-zoster virus (VZV), dengue virus (DENV), human parvovirus B19 (B19), Epstein-Barr virus (EBV), and human herpes virus 6 (HHV-6), which cover the most common pathogenic viruses of FRIs. Detection of the eight FRI-associated viruses, which was divided into two groups/tubes, was simultaneously performed under universal optimized reaction conditions in multiplex one-step real-time RT-PCR assay. The multiplex real-time RT-PCR showed high sensitivity and specificity in detecting the eight FRI-associated viruses. The limits of detection (LODs) for the eight viruses were in the range of 47–177 copies/reaction, and no cross reactions for the eight FRI-associated viruses were found in the multiplex assay. In addition, the results of the multiplex real-time RT-PCR assay were consistent with the results of a monoplex real-time RT-PCR assay and sequencing for clinical specimens obtained from FRI patients. With its advantages of high efficiency and rapid and accurate diagnosis, multiplex real-time RT-PCR was very feasible for the early diagnosis of FRI pathogenic viruses and would be of great help for the proper treatment, monitoring, and initiation of preventive measures for FRI cases.

Rising Incidence of Rubella among Patients With Febrile Rash Illness in a South Western State of Nigeria: a Ten Year Review

Rising Incidence of Rubella among Patients With Febrile Rash Illness in a South Western State of Nigeria: a Ten Year Review

National update on measles cases and outbreaks — United States, January 1 – October 1, 2019

During January 1-October 1, 2019, a total of 1,249 measles cases and 22 measles outbreaks were reported in the United States. This represents the most U.S. cases reported in a single year since 1992 (1), and the second highest number of reported outbreaks annually since measles was declared eliminated* in the United States in 2000 (2). Measles is an acute febrile rash illness with an attack rate of approximately 90% in susceptible household contacts (3). Domestic outbreaks can occur when travelers contract measles outside the United States and subsequently transmit infection to unvaccinated persons they expose in the United States. Among the 1,249 measles cases reported in 2019, 1,163 (93%) were associated with the 22 outbreaks, 1,107 (89%) were in patients who were unvaccinated or had an unknown vaccination status, and 119 (10%) measles patients were hospitalized. Closely related outbreaks in New York City (NYC) and New York State (NYS; excluding NYC), with ongoing transmission for nearly 1 year in large and close-knit Orthodox Jewish communities, accounted for 934 (75%) cases during 2019 and threatened the elimination status of measles in the United States. Robust responses in NYC and NYS were effective in controlling transmission before the 1-year mark; however, continued vigilance for additional cases within these communities is essential to determine whether elimination has been sustained. Collaboration between public health authorities and undervaccinated communities is important for preventing outbreaks and limiting transmission. The combination of maintenance of high national vaccination coverage with measles, mumps, and rubella vaccine (MMR) and rapid implementation of measles control measures remains the cornerstone for preventing widespread measles transmission (4).

Atypical presentation of herpes simplex virus type 1 infection in paediatric burns patients in a large tertiary hospital, South Africa

IntroductionHerpes simplex virus has been reported in the literature to commonly complicate burn wounds. However, there is paucity of such data in the South African setting.Case presentationEight paediatric burns patients with ages ranging between 10 months and 5 years presented with a febrile maculopapular rash illness in a paediatric ward of a large South African tertiary hospital. The rash became vesicular in three cases, involving the limbs and face. Varicella was suspected.Management and outcomeMedical records of suspected cases were reviewed. Blood, vesicular fluid and scab samples were collected. Electron microscopy of vesicular fluid revealed herpes virus particles. Laboratory testing confirmed herpes simplex virus type 1.ConclusionHerpes simplex virus type 1 infection can present atypically in burns patients.